Sirtex Medical Ltd (SXMDF) 21.3700 $SXMDF
Meet the Biotech Company About to Turn the 120-Year-Old Cancer Radiation Industry on Its Head
ACCESSWIRE - Fri Mar 18, 1:49PM CDT
WINDSOR, ON / ACCESSWIRE / March 18, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a new stock pick, Advanced Medical Isotope (OTC: ADMD), which WBT believes has the ability to cause a massive paradigm shift in the cancer treatment space, and potentially capture a large segment of the burgeoning internal radiation therapy market. We look to follow this company as they expect to make another FDA submission later this year, which should catapult the stock if they receive the anticipated marketing clearance. We also contrast and compare a few other companies in the industry.
ATNM: 1.85 (unch), ISR: 0.80 (-0.03), ARAY: 5.67 (+0.06)
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres® Y-90 resin microspheres for Fiscal Year Ending June 30, 2015
PR Newswire - Thu Aug 13, 5:26PM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, today announced dose sales of SIR-Spheres® Y-90 resin microspheres grew 21.2 percent, in the America's region for the fiscal year ending June 30, 2015, compared to the previous corresponding period. Revenue also climbed, up 28.5 percent to $113.4M, with over 7,075 doses being supplied across the region. SIR-spheres Y-90 resin microspheres are available at more than 490 hospitals in the region, up 18 percent from the previous fiscal year.
CORRECTING and REPLACING Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres for Fiscal Year Ending June 30, 2015
BusinessWire - Thu Aug 13, 11:27AM CDT
Headline of release should read: Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres for Fiscal Year Ending June 30, 2015 (instead of Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter).
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter
BusinessWire - Thu Aug 13, 8:08AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, today announced dose sales of SIR-Spheres(R) Y-90 resin microspheres grew 21.2 percent, in the America's region for the fiscal year ending June 30, 2015, compared to the previous corresponding period. Revenue also climbed, up 28.5 percent to $113.4M, with over 7,075 doses being supplied across the region. SIR-spheres Y-90 resin microspheres are available at more than 490 hospitals in the region, up 18 percent from the previous fiscal year.
Sirtex Medical Inc. Half-Year Dose Sales Surge 28 Percent in Advance of SIRFLOX Primary Endpoint Announcement
BusinessWire - Wed Feb 18, 8:13AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company's fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
CNW Group - Thu Jan 29, 10:22AM CST
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 22.80 (+0.17), MMSI: 19.65 (-0.13)
SIR-Spheres® y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO) Clinical Guidelines for Treating Metastatic Colorectal Cancer (mCRC)
CNW Group - Mon Sep 29, 8:13AM CDT
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options.
Meet the Biotech Company About to Turn the 120-Year-Old Cancer Radiation Industry on Its Head
ACCESSWIRE - Fri Mar 18, 1:49PM CDT
WINDSOR, ON / ACCESSWIRE / March 18, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a new stock pick, Advanced Medical Isotope (OTC: ADMD), which WBT believes has the ability to cause a massive paradigm shift in the cancer treatment space, and potentially capture a large segment of the burgeoning internal radiation therapy market. We look to follow this company as they expect to make another FDA submission later this year, which should catapult the stock if they receive the anticipated marketing clearance. We also contrast and compare a few other companies in the industry. ATNM: 1.85 (unch), ISR: 0.80 (-0.03), ARAY: 5.67 (+0.06)
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres® Y-90 resin microspheres for Fiscal Year Ending June 30, 2015
PR Newswire - Thu Aug 13, 5:26PM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, today announced dose sales of SIR-Spheres® Y-90 resin microspheres grew 21.2 percent, in the America's region for the fiscal year ending June 30, 2015, compared to the previous corresponding period. Revenue also climbed, up 28.5 percent to $113.4M, with over 7,075 doses being supplied across the region. SIR-spheres Y-90 resin microspheres are available at more than 490 hospitals in the region, up 18 percent from the previous fiscal year.
CORRECTING and REPLACING Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres for Fiscal Year Ending June 30, 2015
BusinessWire - Thu Aug 13, 11:27AM CDT
Headline of release should read: Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres for Fiscal Year Ending June 30, 2015 (instead of Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter).
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter
BusinessWire - Thu Aug 13, 8:08AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, today announced dose sales of SIR-Spheres(R) Y-90 resin microspheres grew 21.2 percent, in the America's region for the fiscal year ending June 30, 2015, compared to the previous corresponding period. Revenue also climbed, up 28.5 percent to $113.4M, with over 7,075 doses being supplied across the region. SIR-spheres Y-90 resin microspheres are available at more than 490 hospitals in the region, up 18 percent from the previous fiscal year.
Sirtex Medical Inc. Half-Year Dose Sales Surge 28 Percent in Advance of SIRFLOX Primary Endpoint Announcement
BusinessWire - Wed Feb 18, 8:13AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company's fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
CNW Group - Thu Jan 29, 10:22AM CST
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 22.80 (+0.17), MMSI: 19.65 (-0.13)
SIR-Spheres® y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO) Clinical Guidelines for Treating Metastatic Colorectal Cancer (mCRC)
CNW Group - Mon Sep 29, 8:13AM CDT
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options.
